Do online doctors check PMP for Wegovy?

Quick Answer: Yes, you can legally get GLP-1 weight loss medications like Wegovy, Ozempic, and Mounjaro through telehealth in most U.S. states. Because these medications aren’t controlled substances, federal law doesn’t require an in-person visit before prescribing. However, state-specific rules can vary—and understanding these differences is crucial before starting your weight loss journey online.

Understanding Telehealth Prescribing for Weight Loss Medications

The landscape of telehealth weight management has transformed dramatically since 2020. What was once a patchwork of restrictive state laws has evolved into a broadly accessible system—though with important nuances you need to know.

Federal Law: The Foundation

Under federal law, GLP-1 medications (semaglutide and tirzepatide) are not controlled substances. This means the Ryan Haight Act—which historically required in-person exams for controlled drugs—doesn’t apply to weight loss medications like Wegovy, Ozempic, or Mounjaro.

The Drug Enforcement Administration (DEA) has extended COVID-era telehealth flexibilities for controlled substances through December 31, 2025, but this extension doesn’t affect GLP-1 prescribing because those drugs were never restricted in the first place. In practical terms: a licensed healthcare provider can evaluate you via video consultation and send your prescription electronically to a pharmacy, assuming you meet medical criteria and your state allows it.

State-Level Variations: Where It Gets Complicated

While federal law permits telehealth prescribing of these medications, individual states impose their own requirements. Some states require an initial in-person examination, others mandate specific follow-up schedules, and a few have detailed protocols for obesity treatment that extend beyond a simple prescription.

Here’s what you need to know about the most common state requirements:

States Requiring Initial In-Person Exams:

• Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, Texas, and Utah typically expect an initial face-to-face physical examination before or shortly after beginning telehealth weight loss treatment.

States Mandating Periodic Follow-Ups:

• Florida requires patients to have at least one follow-up visit every three months during treatment.
• Virginia requires a check-in approximately 30 days after starting therapy.

States With Comprehensive Initial Workup Requirements:

• New Jersey and Virginia both require extensive baseline evaluations including physical exam, laboratory tests, psychological screening, and documented diet/exercise plans before prescribing weight-loss medications.

States With Full Telehealth Freedom:

• California, Connecticut, Illinois, New York, Pennsylvania, and Washington allow telehealth evaluations without mandating in-person visits for these medications.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Who Can Prescribe Weight Loss Medications via Telehealth?

Understanding provider credentials matters, especially in telehealth settings where you may see different types of clinicians.

Medical Doctors (MDs) and Doctors of Osteopathy (DOs)

All states permit fully licensed MDs and DOs to prescribe GLP-1 weight loss medications via telehealth, provided they hold an active license in the state where the patient is physically located during the consultation.

Nurse Practitioners (NPs) and Physician Assistants (PAs)

This is where state regulations diverge significantly:

Independent Practice States (34+ states as of 2025):States like California, Washington, New York, Arizona, and Utah allow Nurse Practitioners to practice independently without physician oversight after meeting experience requirements. In these states, NPs can evaluate patients and prescribe weight loss medications entirely on their own.

Collaborative Practice States:States such as Texas, Florida, Georgia, and Pennsylvania require NPs and PAs to maintain formal collaboration or supervision agreements with physicians. They can still prescribe GLP-1 medications, but within the framework of physician oversight.

Recent Expansions:Georgia passed legislation in 2024 allowing NPs and PAs to prescribe Schedule II controlled substances with physician delegation for the first time—a significant expansion that signals growing trust in advanced practice providers, though it doesn’t directly affect non-controlled GLP-1 drugs.

At Klarity Health, all providers—whether MDs, DOs, NPs, or PAs—are fully licensed and credentialed in the states where they practice, ensuring you receive care that meets both state and federal requirements.

The Medications: What You Can Get Through Telehealth

Wegovy (Semaglutide 2.4mg)

FDA Status: Approved for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidities.

Telehealth Availability: ✅ Fully available via telehealth in all states (subject to state-specific rules above).

Important Note: The FDA ended emergency allowances for compounded semaglutide in May 2025. You should only receive FDA-approved, brand-name Wegovy from licensed pharmacies—not compounded versions from non-traditional sources.

Typical Supply: Initial prescriptions are often 4-week supplies to assess tolerance. Stable patients may receive 30-90 day prescriptions with appropriate follow-up.

Ozempic (Semaglutide 0.5-1mg)

FDA Status: Approved for Type 2 diabetes; commonly prescribed off-label for weight loss.

Telehealth Availability: ✅ Available via telehealth when prescribed off-label for obesity.

What ‘Off-Label’ Means: Your provider must document the medical rationale for using this diabetes medication for weight loss and obtain your informed consent. Reputable telehealth services will explain this clearly and ensure you meet obesity treatment criteria.

Key Consideration: Ozempic contains the same active ingredient as Wegovy. You should never take both simultaneously.

Mounjaro (Tirzepatide) / Zepbound

FDA Status: Mounjaro is approved for Type 2 diabetes. Zepbound (the higher-dose obesity formulation of tirzepatide) received FDA approval in late 2023.

Telehealth Availability: ✅ Available via telehealth for qualified patients.

Clinical Notes: Tirzepatide works through a dual mechanism (GLP-1 and GIP receptors) and has shown impressive weight loss results in clinical trials. Like other GLP-1s, it requires patient training on self-injection technique.

Medical Eligibility: Who Qualifies for Telehealth Weight Loss Treatment?

Clinical Criteria

Legitimate telehealth providers screen carefully. You generally need:

Body Mass Index (BMI):

• BMI ≥30 (obesity), OR
• BMI ≥27 with at least one weight-related health condition (such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea)

Age:Most GLP-1 medications are approved for adults 18+. Some formulations have specific age restrictions.

Weight Loss Attempts:Providers typically want to see evidence that you’ve tried lifestyle modifications (diet and exercise) unless medically contraindicated. This isn’t about blame—it’s about ensuring medication is appropriate for your situation.

Contraindications and Safety Screening

Reputable telehealth services will screen you for conditions that make GLP-1 therapy unsafe:

Absolute Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning to become pregnant (must discontinue 2 months before conception)
• Previous severe allergic reaction to semaglutide or tirzepatide

Relative Contraindications (Require Careful Evaluation):

• History of pancreatitis
• Severe gastroparesis or gastrointestinal disorders
• Active gallbladder disease
• History of eating disorders
• Diabetic retinopathy (particularly with rapid glucose changes)
• Severe kidney disease

A thorough telehealth intake should ask about all these conditions. If a service doesn’t inquire about medical history in detail, that’s a red flag.

What to Expect: The Telehealth Weight Loss Journey

Initial Consultation

A legitimate telehealth visit for weight loss medication should include:

1. Comprehensive Medical History: Detailed questions about current medications, allergies, previous weight loss attempts, mental health, and family medical history.

2. Current Measurements: You’ll provide current weight and height (some services may require photo verification or ask you to weigh in during the video call).

3. Live Video Assessment: A real-time conversation with a licensed provider—not just a questionnaire. Expect 15-30 minutes minimum.

4. Risk Discussion: Your provider should explain potential side effects (nausea, vomiting, diarrhea, constipation, potential gallbladder issues, rare but serious risks like pancreatitis).

5. Lifestyle Counseling: Discussion of diet, exercise, behavioral changes, and realistic expectations (typically 1-2 pounds per week weight loss).

6. Treatment Plan: Clear documentation of your goals, the medication prescribed, dosing schedule, follow-up plan, and when to seek medical attention.

Ongoing Monitoring

Weight loss medication isn’t a ‘prescribe and forget’ treatment. Expect:

Frequent Early Follow-Ups:Most providers schedule a check-in within 2-4 weeks of starting medication to assess tolerance and side effects.

Regular Monitoring:Ongoing consultations every 1-3 months to:

• Track weight loss progress
• Adjust medication dosage as needed
• Monitor for side effects
• Review lab work (many providers order baseline and periodic metabolic panels, liver function tests, and lipid panels)
• Ensure continued medical appropriateness

State-Mandated Follow-Ups:Remember, some states legally require specific follow-up schedules (Florida’s 3-month rule, Virginia’s 30-day initial follow-up, etc.). Your telehealth provider should build these requirements into your treatment plan.

Cost Considerations

With Insurance:GLP-1 medications for weight loss often face coverage challenges. Many insurance plans cover these drugs only for diabetes (Ozempic, Mounjaro) and not for obesity alone (Wegovy). Klarity Health accepts both insurance and self-pay options, helping you navigate coverage questions transparently.

Self-Pay:Without insurance, expect:

• Telehealth consultation fees: typically $50-200 per visit
• Medication costs: $900-1,300+ per month for brand-name products without insurance
• Some telehealth platforms offer membership models with bundled pricing

Klarity Health provides transparent pricing upfront, so you know exactly what to expect—no surprise bills.

Red Flags: How to Spot Unsafe Telehealth Weight Loss Services

The popularity of GLP-1 medications has unfortunately attracted some questionable operators. Protect yourself by watching for these warning signs:

Guarantees Without Evaluation

Red Flag: Any service that guarantees you’ll receive a prescription before you’ve had a comprehensive medical evaluation.

What’s Legitimate: Telehealth providers should make clear that prescription depends on medical appropriateness. Not everyone qualifies.

Compounded or ‘Generic’ Semaglutide

Red Flag: Offers for compounded semaglutide, overseas ‘generic’ versions, or significant discounts on ‘the same medication’ as Wegovy.

What You Should Know: The FDA banned routine compounding of semaglutide in May 2025 after declaring the shortage over. Compounded versions are only legal in very specific circumstances (patient-specific allergies, etc.) and require special pharmacy protocols. Overseas versions may not meet FDA safety standards.

What’s Legitimate: FDA-approved brand-name medications dispensed from U.S.-licensed pharmacies.

Questionnaire-Only ‘Evaluation’

Red Flag: Services that base prescriptions solely on a written questionnaire without any live provider interaction.

What’s Legitimate: Federal and state laws require a valid patient-provider relationship, which generally means a real-time audio-visual consultation (video visit) for initial prescriptions.

No Follow-Up or Monitoring

Red Flag: Services that don’t schedule or require any follow-up appointments, or that offer unlimited refills without check-ins.

What’s Legitimate: Responsible weight loss treatment includes regular monitoring for safety and effectiveness. Providers should refuse to continue prescribing if you’re not meeting for scheduled follow-ups.

Unclear Provider Credentials

Red Flag: You can’t easily find out who your prescriber is, what their credentials are, or what state(s) they’re licensed in.

What’s Legitimate: Transparent disclosure of provider names, credentials (MD, DO, NP, PA), and license verification. The provider must be licensed in the state where you’re physically located.

Pressure Tactics

Red Flag: High-pressure sales language, claims that you’ll ‘miss out’ if you don’t sign up immediately, or testimonials that seem too good to be true.

What’s Legitimate: Professional healthcare services present options clearly, answer questions thoroughly, and let you make informed decisions without pressure.

State-by-State Breakdown: Where You Can Access Telehealth Weight Loss Treatment

Here’s a detailed look at regulations in key states (current as of December 2025):

High-Access States (Minimal Restrictions)

California: Full telehealth freedom. NPs practice independently. No mandated in-person visits for GLP-1 prescribing. E-prescribing standard practice.

New York: Telehealth exam sufficient to establish patient-provider relationship. NPs have independent authority after 3,600 supervised hours. Mandatory e-prescribing since 2016.

Washington: Pioneer in telehealth access. No in-person requirements. NPs have full practice authority. Note: Washington’s My Health My Data Act (2023) adds extra privacy protections for sensitive health data—telehealth providers must comply with enhanced data security rules.

Illinois: Permanent telehealth law allows virtual weight loss treatment. Collaborative practice for NPs (written MD agreement required). Mandatory e-prescribing for all medications since 2023.

Moderate-Access States (Some Requirements)

Florida: No in-person exam required, but state obesity treatment law requires BMI ≥30 and follow-up visits at least every 3 months. NPs have limited independent authority (mostly in primary care settings, not specialized obesity treatment). Prescribers must document comprehensive treatment plan including lifestyle modifications.

Georgia: Requires initial in-person examination before telehealth weight loss prescriptions. 2024 law now allows NPs/PAs to prescribe Schedule II drugs with physician delegation (previously prohibited)—though this doesn’t affect non-controlled GLP-1s, it signals regulatory modernization.

Virginia: Requires initial in-person physical exam, baseline lab work, psychological screening, and documented diet/exercise plan. Follow-up within 30 days of starting therapy is mandatory. NPs have independent authority after 2 years of collaborative practice.

Texas: Generally expects initial in-person examination for weight management prescriptions. Very strict NP/PA oversight—prescriptive authority requires formal physician delegation agreement. NPs cannot practice independently (2023 full practice authority bill failed). DEA telehealth extensions allow controlled substance prescribing through 2025, but this doesn’t affect GLP-1s (which were never restricted).

Restricted-Access States (Multiple Requirements)

New Jersey: Among the most stringent. Requires comprehensive initial in-person evaluation including physical exam, extensive lab work, psychological assessment, and documented risks discussion. NPs must maintain joint protocols with physicians (full practice authority legislation has stalled). Strong consumer protection focus but creates access barriers.

Arkansas: One of the nation’s most restrictive telehealth states overall. Requires initial in-person encounter to establish patient-provider relationship for most prescribing. NPs require MD collaboration agreements. Proposals to ease restrictions under review as of late 2025.

Mississippi: Requires initial in-person evaluation for weight management therapy. NPs work under collaborative agreements (though full practice authority bills were introduced in 2024-2025 legislative sessions). Traditional approach to obesity treatment regulation.

Privacy and Data Security in Telehealth Weight Loss Care

Your health information—especially weight-related data—deserves protection. When choosing a telehealth provider for weight loss treatment, verify:

HIPAA Compliance

All telehealth platforms must comply with the Health Insurance Portability and Accountability Act (HIPAA). This means:

• Encrypted video platforms for consultations
• Secure messaging systems
• Protected storage of medical records
• Limited access to your health information
• Clear policies on who can view your data

State Privacy Laws

Several states have enacted additional privacy protections beyond HIPAA:

Washington’s My Health My Data Act: Requires specific safeguards for sensitive health data, including weight and body measurements. Telehealth providers serving Washington residents must obtain explicit consent for data collection and use.

California Consumer Privacy Act (CCPA): While primarily focused on consumer data broadly, CCPA gives California residents rights to know what personal information is collected and request deletion.

Ask your telehealth provider:

• Where is my health data stored?
• Who has access to my information?
• Do you sell or share my data with third parties?
• How can I access or delete my records?

At Klarity Health, we prioritize your privacy with HIPAA-compliant systems, encrypted communications, and transparent data practices. We never sell your health information, and you maintain full rights to your medical records.

The Future of Telehealth Weight Loss Treatment

Regulatory Trends to Watch

DEA Rules for 2026 and Beyond:The current telehealth flexibilities for controlled substances expire December 31, 2025. While this doesn’t directly affect GLP-1 prescribing (since they’re not controlled), a 4th extension or new permanent rule is expected. The proposed TREATS Act, if passed, would make some telehealth flexibilities permanent—signaling Congressional support for expanded telehealth access.

State Modernization:At least five states are considering legislation in 2026 to expand NP/PA independent practice authority and streamline telehealth requirements. The trend is clearly toward greater access with appropriate clinical safeguards.

FDA Oversight:Following the 2025 compounding ban, expect continued scrutiny of alternative GLP-1 formulations and compound medications. The FDA has signaled it will closely monitor ‘work-arounds’ that might compromise patient safety.

Emerging Medications

Several new anti-obesity medications are in late-stage development:

• Oral GLP-1 formulations (potentially easier than injections)
• Triple-agonist medications (targeting GLP-1, GIP, and glucagon receptors)
• Combination therapies pairing GLP-1s with other mechanisms

As these reach the market, expect telehealth access models to adapt quickly, potentially with similar regulatory frameworks to current GLP-1 prescribing.

Practical Tips for Starting Telehealth Weight Loss Treatment

Before Your First Appointment

Gather Information:

• Current weight and height
• List of all medications and supplements
• Medical history (previous diagnoses, surgeries, hospitalizations)
• Family health history
• Previous weight loss attempts and results
• Current diet and exercise habits

Prepare Questions:

• What are realistic expectations for weight loss?
• What side effects might I experience?
• How will we monitor my progress?
• What happens if the medication doesn’t work for me?
• What’s the long-term plan—will I take this medication indefinitely?

Check Your Insurance:If using insurance, call your plan beforehand to understand:

• Is this medication covered for weight loss (not just diabetes)?
• What’s my copay or coinsurance?
• Is prior authorization required?
• Are there preferred pharmacies?

During Treatment

Be Honest:Report all side effects, even mild ones. Your provider can adjust dosing or provide strategies to minimize discomfort.

Follow Lifestyle Recommendations:These medications work best alongside healthy eating and physical activity. They’re not magic pills—think of them as powerful tools that work when you do.

Attend Follow-Ups:Even if you’re feeling great, keep scheduled appointments. Monitoring ensures safety and optimizes results.

Track Progress:Beyond the scale, note improvements in:

• Energy levels
• Joint pain or mobility
• Sleep quality
• Blood pressure or glucose levels (if applicable)
• Clothing fit and body measurements

If You’re Not Seeing Results

After 12-16 weeks at therapeutic dosing, you should see significant weight loss (typically 5-10% or more of starting weight). If not:

Talk to Your Provider About:

• Medication adherence (are you taking it correctly?)
• Diet and activity assessment
• Potential medication adjustments or alternatives
• Underlying conditions affecting weight loss (thyroid issues, PCOS, etc.)
• Whether this medication is right for you

Not everyone responds equally to GLP-1 medications. A good provider will work with you to find the best approach—which might mean switching medications, adjusting dosing, or considering other treatments.

How Klarity Health Makes Telehealth Weight Loss Treatment Accessible

At Klarity Health, we’ve designed our weight management program around three core principles: accessibility, affordability, and quality care.

Provider Availability

Unlike platforms where you might wait weeks for an appointment, Klarity offers:

• Same-day and next-day appointment options in most states
• Extended hours including evenings and weekends
• Video visits from the comfort of your home
• Licensed providers in all states we serve (AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA)

Transparent Pricing

We believe healthcare costs shouldn’t be mysterious. Klarity provides:

• Upfront pricing for consultations—you’ll know the cost before booking
• Insurance and self-pay options—we work with your insurance when possible and offer clear self-pay rates when insurance doesn’t cover weight loss treatment
• No hidden fees—what you see is what you pay
• Help navigating insurance prior authorizations and appeals

Comprehensive Care

Our weight management program includes:

• Initial comprehensive evaluation (typically 30+ minutes)
• Personalized treatment plan including medication and lifestyle guidance
• Regular follow-up appointments to monitor progress
• Coordination with your primary care provider (with your permission)
• Support team available to answer questions between appointments
• Resources for nutrition, exercise, and behavioral strategies

We treat you as a whole person, not just a prescription candidate. If GLP-1 medication isn’t right for you, we’ll discuss alternatives honestly—because our goal is your long-term health, not just writing prescriptions.

Frequently Asked Questions

Q: Can I get Wegovy prescribed online without ever seeing a doctor in person?

A: In most states, yes—you can complete your entire evaluation via video consultation with a licensed provider. However, states like Arkansas, Georgia, New Jersey, South Carolina, and Texas may require an initial in-person examination. Check the state-specific regulations in this guide or ask your telehealth provider about your state’s requirements.

Q: How long does a telehealth weight loss appointment take?

A: Initial consultations typically last 20-40 minutes to ensure thorough evaluation. Follow-up appointments are usually 10-20 minutes, depending on what you need to discuss.

Q: Will my insurance cover telehealth weight loss medication?

A: Coverage varies significantly. Many plans cover GLP-1 medications for diabetes (Ozempic, Mounjaro) but not specifically for weight loss (Wegovy). Some plans have recently added weight loss coverage due to proven health benefits. Klarity Health can help you verify your coverage and navigate prior authorizations.

Q: What if I move to a different state during treatment?

A: Your provider must be licensed in the state where you’re physically located during each appointment. If you move, inform your telehealth service. They may have providers licensed in your new state, or they can help transition your care appropriately.

Q: Are there any age restrictions for these medications?

A: Most GLP-1 weight loss medications are FDA-approved for adults 18 and older. Some formulations have approval for adolescents (12+) with obesity, but this typically requires different evaluation criteria and often in-person care.

Q: How quickly will I lose weight on these medications?

A: Results vary, but clinical trials show average weight loss of 5-10% of body weight by 12 weeks, with continued loss up to 15-20% or more over 12-18 months when combined with lifestyle changes. Weight loss is gradual—expect 1-2 pounds per week on average, not rapid drops.

Q: What happens if I can’t afford the medication?

A: Several options exist:

• Patient assistance programs from manufacturers (income-based discounts)
• Manufacturer savings cards (if you have commercial insurance)
• Alternative medications with better coverage
• Discussion with your provider about treatment timing or alternatives

Be wary of ‘cheap compounded’ versions—as of 2025, these are largely illegal for routine weight loss use and may pose safety risks.

Q: Can I stop taking the medication once I reach my goal weight?

A: GLP-1 medications are typically considered long-term treatments. Many people regain weight when discontinuing. Your provider will help you make decisions about continuing medication, transitioning to a lower maintenance dose, or developing strategies to sustain weight loss after stopping—but be prepared for this to be a long-term commitment, much like managing other chronic conditions.

Taking the Next Step

If you’re considering telehealth weight loss treatment, you’re exploring a proven, safe, and increasingly accessible option. The key is choosing a reputable provider who prioritizes your health over quick prescriptions.

Before booking your first appointment:

✅ Verify the provider is licensed in your state
✅ Confirm you meet medical criteria (BMI, health conditions)
✅ Prepare your medical history and current medication list
✅ Understand your state’s specific requirements
✅ Check insurance coverage or review self-pay pricing
✅ Ensure the service includes ongoing monitoring, not just initial prescription

At Klarity Health, we’re committed to making evidence-based weight management accessible to everyone who can benefit. Our licensed providers are available across multiple states, we accept both insurance and self-pay, and we offer transparent pricing so there are no surprises.

Ready to explore your options? Schedule a consultation with Klarity Health to discuss whether GLP-1 weight loss medication is right for you. Our providers will take time to understand your health history, explain treatment options clearly, and help you make informed decisions about your weight management journey—all from the convenience of a video visit.

Your healthier future is just a consultation away. Let’s start the conversation.

Citations and Sources

This article incorporates the most current regulatory information available as of December 17, 2025. Key sources include:

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – U.S. Drug Enforcement Administration, November 15, 2024. Official announcement confirming extension of COVID-era telehealth rules for controlled substances through December 31, 2025. www.dea.gov

2. COVID-era Telehealth Prescribing Extended – Axios News, November 18, 2024. News coverage of the DEA’s third extension of telehealth flexibilities, providing context on implications for patient access. www.axios.com

3. The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter LLP, March 27, 2024. Comprehensive legal analysis of state-specific requirements for prescribing GLP-1 medications, including detailed coverage of Florida, New Jersey, and Virginia regulations. www.goodwinlaw.com

4. Know Your State’s Laws Around Semaglutide – Nextech Blog, April 11, 2025. State-by-state breakdown of prescribing requirements, in-person exam mandates, and provider authority across multiple jurisdictions. www.nextech.com

5. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery, November 18, 2024. Expert legal analysis explaining the distinction between controlled substances (subject to Ryan Haight Act) and non-controlled medications like GLP-1 agonists. www.mwe.com

This article is for informational purposes only and does not constitute medical advice. Consult with a licensed healthcare provider to determine if telehealth weight loss treatment is appropriate for your individual situation. Regulations vary by state and are subject to change.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid